The “When” Matters: Evidence From Memory Markers in the Clinical Continuum of Alzheimer’s Disease

Simple item page
dc.coverageDOI: 10.1037/neu0000891
dc.creatorForno, Gonzalo
dc.creatorParra, Mario A.
dc.creatorThumala, Daniela
dc.creatorVillagra, Roque
dc.creatorCerda, Mauricio
dc.creatorZitko, Pedro
dc.creatorIbañez, Agustín
dc.creatorLillo, Patricia
dc.creatorSlachevsky, Andrea
dc.date2023
dc.date.accessioned2026-01-05T21:17:19Z
dc.date.available2026-01-05T21:17:19Z
dc.description<p>Objective: Cognitive assessment able to detect impairments in the early neuropathological stages of Alzheimer’s disease (AD) is urgently needed. The visual short-term memory binding task (VSTMBT) and the Free and Cued Selective Reminding Test (FCSRT) have been recommended by the neurodegenerative disease working group as promising tests to aid in the early detection of AD. In this study, we investigated their complementary value across the clinical stages of the AD continuum. Method: One hundred and seventeen older adults with subjective cognitive complaint (SCC), 79 with mild cognitive impairment (MCI), 31 patients with AD dementia (ADD), and 37 cognitively unimpaired (CU) subjects, underwent assessment with the VSTMBT and the picture version of the Spanish FCSRT. Results: After controlling for multiple comparisons, significant differences were found across groups. The VSTMBT was the only test that “marginally” differentiated between CU and SCC (d = 0.47, p =.052). Moreover, whereas the FCSRT showed a gradient (CU = SCC) &gt; MCI &gt; ADD, the VSTMBT gradient was CU &gt; SCC &gt; (MCI = ADD) suggesting that conjunctive binding deficits assessed by the latter may be sensitive to the very early stages of the disease. Conclusions: Our results suggest that the VSTMBT and the FCSRT are sensitive to the clinical continuum of AD. Whereas the former detects changes in the early prodromal stages, the latter is more sensitive to the advanced prodromal stages of AD. These novel tests can aid in the early detection, monitor disease progression and response to treatment, and thus support drug development programs.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/3419241c-85a2-44ad-a7b5-bac7d7af007b
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/67503
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.37 (2023) date: 2023-05-25 nr.7 p.753-768
dc.subjectAlzheimer’s disease continuum
dc.subjectcognitive complaint
dc.subjectearly detection
dc.subjectmemory binding
dc.subjectrelational memory
dc.titleThe “When” Matters: Evidence From Memory Markers in the Clinical Continuum of Alzheimer’s Diseaseeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
Pure-CRIS